According to NICE Clinical Knowledge Summaries, once B12 deficiency is adequately treated and symptoms resolve, routine monitoring of serum B12 levels is generally unnecessary, as clinical response is the primary indicator of treatment effectiveness
Potential Side Effects and Safety Considerations Vitamin B12 injections are generally well-tolerated with an excellent safety profile when administered appropriately
Standard Cagrilintide Monotherapy Chart CAGRILINTIDE ESCALATION PROTOCOL Week 1-4: [0.6 mg] Tolerance Assessment Week 5-8: [1.2 mg] Efficacy & Safety Review Week 9+: [2.4 mg] Maintenance Monitoring Theoretical Combination Dosing Chart For cagrilintide dosage with tirzepatide , a theoretical combination chart might look like: COMBINATION PROTOCOL (THEORETICAL) TIRZEPATIDE CAGRILINTIDE Week 1-4: 2.5 mg None Week 5-8: 5.0 mg None Week 9-12: 7.5 mg None Week 13-16: 7.5 mg 0.6 mg Introduction Week 17-20: 10 mg 1.2 mg Week 21+: 12.5 mg 2.4 mg Optimization This staged approach minimizes the risk of overwhelming gastrointestinal side effects while allowing for individualized dose optimization
In 2023, during Bidens Presidency, the Food and Drug Administration placed nineteen peptides, including BPC-157, on a do not compound list, citing potential significant safety risks that included immune reactions, pancreatitis, and accelerated growth of cancerous cells
Many researchers inject MOTS-C in the morning and Retatrutide in the evening when they fall on the same day
